{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.5","upperLimit":"18.9","value":"5.2"},{"groupId":"OG001","lowerLimit":"4.4","upperLimit":"22.5","value":"11.1"},{"groupId":"OG002","lowerLimit":"1.5","upperLimit":"22.5","value":"5.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"49"}],"units":"Participants"}],"description":"Median cumulative total number of CD34+ cells collected during apheresis.","dispersionType":"Full Range","groups":[{"description":"Participants with NHL were mobilized with granulocyte colony-stimulating factor (G-CSF) 10 µg/kg/day for 4 days. Plerixafor 240 µg/kg was given the evening of day 4 and G-CSF given the next morning followed by apheresis. Evening doses of plerixafor and morning doses of G-CSF followed by apheresis continued for up to a maximum of 5 aphereses or until ≥ 5\\*10\\^6 CD34+ cells/kg were collected.","id":"OG000","title":"Non-Hodgkin's Lymphoma (NHL)"},{"description":"Participants with MM were mobilized with granulocyte colony-stimulating factor (G-CSF) 10 µg/kg/day for 4 days. Plerixafor 240 µg/kg was given the evening of day 4 and G-CSF given the next morning followed by apheresis. Evening doses of plerixafor and morning doses of G-CSF followed by apheresis continued for up to a maximum of 5 aphereses or until ≥ 5\\*10\\^6 CD34+ cells/kg were collected.","id":"OG001","title":"Multiple Myeloma (MM)"},{"id":"OG002","title":"All Participants"}],"paramType":"MEDIAN","populationDescription":"Participants who received at least one dose of plerixafor","reportingStatus":"POSTED","timeFrame":"Days 5-8","title":"Median Cumulative Number of CD34+ Cells Collected During Apheresis","type":"OTHER_PRE_SPECIFIED","unitOfMeasure":"CD34+ cells (*10^6 / kg)"}